3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 1/2
3
Phase 3
2
Phase EARLY_PHASE1
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
62
Myelodysplastic Syndromes
33
Leukemia, Myelomonocytic, Chronic
16
Leukemia
16
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Myelomonocytic, Acute
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Monocytic, Acute
5
Hodgkin Disease
5
Myeloproliferative Disorders
4
Congenital Abnormalities
4
Anemia, Refractory, with Excess of Blasts
4
Thrombocythemia, Essential
3
Primary Myelofibrosis
3
Polycythemia Vera
3
Lymphoma
3
Blast Crisis
3
Triple Negative Breast Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasm, Residual
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
Decitabine
×
Clear all
NCT02664181
2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2
Completed
13 enrolled
14 charts